

CLOSING IN ON A CURE

2017 Alzheimer's Clinical Trials Report



Alzheimer's
Drug Discovery
Foundation

Data Table

Complete Report is Available from AlzDiscovery.org

*Intervention received support from the ADDF

Intervention	Sponsors & Collaborators	Phase	Type of Therapy	Path to Clinic	Primary Target	Secondary Target	Relevant Links	Other Names Mechanism of Action
AADvac1	Axon Neuroscience SE	Phase 2	Biologic	Novel	Misfolded Proteins	Tau	https://ClinicalTrials.gov/show/NCT02579252	AC-AD-003 Axon peptide 108 conjugated to KLH
ABBV-8E12	AbbVie	Phase 2	Biologic	Novel	Misfolded Proteins	Tau	https://ClinicalTrials.gov/show/NCT02880956	
Abvac40	Araclon Biotech	Phase 2	Biologic	Novel	Misfolded Proteins	Amyloid	https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-004352-30/ES	
AC-1204	Accera, Inc.	Phase 2 Phase 3	Natural Product	Other	Mitochondria & Metabolic Function		https://ClinicalTrials.gov/show/NCT01741194	Ketogenic
ACI-24	AC Immune SA	Phase 2	Biologic	Novel	Misfolded Proteins	Amyloid	https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-006257-40/DK	Pal1-15 acetate salt
ACI-35	AC Immune SA Janssen	Phase 1	Biologic	Novel	Misfolded Proteins	Tau	http://www.acimmune.com/en/ad-treatment-and-prevention/#aci-35	
Adipose Derived Stromal Cells	Ageless Regenerative Institute	Phase 1 Phase 2	Cell Therapy	Novel	Neuroprotection		https://clinicaltrials.gov/ct2/show/NCT02912169	Autologous Adipose-Derived Stromal Cells
Aducanumab	Biogen	Phase 3	Biologic	Novel	Misfolded Proteins	Amyloid	https://ClinicalTrials.gov/show/NCT02484547 https://clinicaltrials.gov/show/NCT02477800	BIIB037 Microglial-mediated phagocytosis and clearance of amyloid
AGB101 *	Agenebio, Inc.	Phase 2 completed	Small Molecule	Repurposed	Synaptic Activity & Neurotransmitters		https://clinicaltrials.gov/ct2/show/NCT01044758	Low-dose levetiracetam Pre-synaptic calcium channel inhibitor

Albumin Immune globulin	Instituto Grifols, S.A. Grifols Biologicals Inc.	Phase 2 Phase 3	Biologic	Repurposed	Misfolded Proteins	Amyloid	https://ClinicalTrials.gov/show/NCT01561053	Intravenous Immunoglobulin, Human Albumin Combined With Flebogamma
Allopregnanolone *	University of Southern California National Institute on Aging (NIA)	Phase 1 completed	Biologic	Other	Neuroprotection	Neuronal Regeneration & Repair	https://ClinicalTrials.gov/show/NCT02221622	3 α ,5 α -tetrahydroprogesterone, 3 α -hydroxy-5 α -pregnan-20-one
ALZ-801	Alzheon	Phase 1	Small Molecule	Other	Misfolded Proteins	Amyloid	https://alzheon.com/underlying-clinical-data/	Tramiprosate Amyloid aggregation inhibitor, activity at GABA synapse (unclear if agonist or antagonist)
ALZT-OP1	AZTherapies, Inc. PharmaConsulting Group KCAS Bio APCER Life Sciences	Phase 3	Small Molecule	Repurposed (Combination Therapy)	Inflammation	Neuroinflammation	https://ClinicalTrials.gov/show/NCT02547818	Cromolyn sodium, Ibuprofen
ANAVEX2-73	Anavex Life Sciences Corp.	Phase 2	Small Molecule	Novel	Neuroprotection		https://clinicaltrials.gov/show/NCT02756858	Sigma1/muscarinic receptor binder, intracellular sigma-1 chaperone protein agonist
AstroStem	Nature Cell Co. Ltd.	Phase 1 Phase 2	Cell Therapy	Novel	Neuroprotection		https://ClinicalTrials.gov/show/NCT03117738	Autologous fat stem cells
Atomoxetine *	Emory University National Institute on Aging (NIA)	Phase 2	Small Molecule	Repurposed	Synaptic Activity & Neurotransmitters		https://ClinicalTrials.gov/show/NCT01522404	ATX-001 Norepinephrine reuptake inhibitor
AZD0530	Yale University Alzheimer's Therapeutic Research Institute	Phase 2	Small Molecule	Repositioned	Neuroprotection	Neurodegeneration	https://clinicaltrials.gov/show/NCT02167256	Saracatinib Kinase inhibitor; Src tyrosine kinase inhibitor (NCATS molecule)
Azeliragon	vTv Therapeutics	Phase 3	Small Molecule	Novel	Inflammation	Neuroinflammation	https://ClinicalTrials.gov/show/NCT02916056 https://ClinicalTrials.gov/show/NCT02080364	F-04494700, TTP488 RAGE inhibitor
BAC	Charsire Biotechnology Corp. A2 Healthcare Taiwan Corporation	Phase 2	Unknown	Unknown	Unknown		https://ClinicalTrials.gov/show/NCT02467413 https://clinicaltrials.gov/show/NCT02886494	BAC-01, BAC-02 Bacterial artificial chromosome (BAC)
BAN2401	Eisai Inc. Biogen	Phase 2	Biologic	Novel	Misfolded Proteins	Amyloid	https://ClinicalTrials.gov/show/NCT01767311	

Benfotiamine *	Burke Medical Research Institute Burke Rehabilitation Hospital Columbia University National Institute on Aging (NIA) Alzheimer's Drug Discovery Foundation	Phase 2	Small Molecule	Repurposed	Mitochondria & Metabolic Function		https://ClinicalTrials.gov/show/NCT02292238	BRC-451, 1R01AG043679-01A1 Vitamin B1 type antioxidant
BI 409306	Boehringer Ingelheim	Phase 2	Small Molecule	Novel	Synaptic Activity & Neurotransmitters		https://clinicaltrials.gov/show/NCT02240693 https://clinicaltrials.gov/show/NCT02337907 https://clinicaltrials.gov/show/NCT02392468	Phosphodiesterase 9A inhibitor
BIIB076	Biogen	Phase 1	Biologic	Novel	Misfolded Proteins	Tau	https://ClinicalTrials.gov/show/NCT03056729	Anti-tau monoclonal antibody
Bisnorcymserine (BNC)	National Institute on Aging (NIA) National Institutes of Health Clinical Center (CC)	Phase 1	Small Molecule	Novel	Synaptic Activity & Neurotransmitters		https://ClinicalTrials.gov/show/NCT01747213	Butyrylcholinesterase inhibitor
BPN14770 *	Tetra Discovery Partners	Phase 1 completed	Small Molecule	Novel	Synaptic Activity & Neurotransmitters		https://ClinicalTrials.gov/show/NCT02840279 https://clinicaltrials.gov/show/NCT02648672	Negative allosteric modulator of phosphodiesterase 4D
Bryostatin 1 *	Neurotrope Bioscience, Inc.	Phase 2	Small Molecule	Other	Neuroprotection	Neuronal Regeneration & Repair	https://ClinicalTrials.gov/show/NCT02431468	Protein kinase C modulator
Candesartan *	Emory University	Phase 2	Small Molecule	Repurposed	Vascular		https://ClinicalTrials.gov/show/NCT02646982	Angiotensin receptor blocker
CB-AC-02	CHABiotech CO., Ltd	Phase 1 Phase 2	Cell Therapy	Novel	Neuroprotection		https://ClinicalTrials.gov/show/NCT02899091	Placenta derived-MSCs
Cilostazol	National Cerebral and Cardiovascular Center, Japan	Phase 2	Small Molecule	Repurposed	Vascular		https://clinicaltrials.gov/ct2/show/NCT02491268	Vasodilator, phosphodiesterase 3 antagonist
CNP520	Novartis Pharmaceuticals Amgen Banner Alzheimer's Institute Novartis	Phase 2 Phase 3	Small Molecule	Novel	Misfolded Proteins	Amyloid	https://ClinicalTrials.gov/show/NCT03131453	BACE1 inhibitor

CNP520 CAD106	Novartis Pharmaceuticals Banner Alzheimer's Institute National Institute on Aging (NIA) Alzheimer's Association Amgen	Phase 2 Phase 3	Small Molecule + Biologic	Novel (Combination Therapy)	Misfolded Proteins	Amyloid	https://ClinicalTrials.gov/show/NCT02565511	Amyloid antibody, BACE1 inhibitor
CPC-201	Chase Pharmaceuticals Corporation	Phase 2	Small Molecule + Biologic	Novel + Donepezil (Combination Therapy)	Synaptic Activity & Neurotransmitters		https://clinicaltrials.gov/show/NCT02549196 https://clinicaltrials.gov/show/NCT02860065	Combination of Donepezil (an acetylcholinesterase inhibitor) with a peripherally acting cholinergic blocker
Crenezumab	Hoffmann-La Roche Genentech AC Immune	Phase 2 Phase 3	Biologic	Novel	Misfolded Proteins	Amyloid	https://ClinicalTrials.gov/show/NCT02670083 NCT01998841 NCT03114657	MABT5102A, RG7412 Amyloid phagocytosis stimulator
CSP-1103	CereSpir	Phase 2 completed	Small Molecule	Novel	Inflammation	Neuroinflammation	https://clinicaltrials.gov/ct2/show/NCT01303744	CHF 5074 Microglia 'M2' inducer
CT1812 *	Cognition Therapeutics	Phase 1 Phase 2	Small Molecule	Novel	Neuroprotection	Neurodegeneration	https://ClinicalTrials.gov/show/NCT02907567	Sigma2/PGRMC1 receptor binder
DHP1401 Donepezil	Daehwa Pharmaceutical Co., Ltd.	Phase 2	Small Molecule	Novel + Donepezil (Combination Therapy)	Synaptic Activity & Neurotransmitters		https://clinicaltrials.gov/ct2/show/NCT03055741	Combination of Donepezil (an acetylcholinesterase inhibitor) with AMPA receptor modulator, MAPK modulator, protein kinase modulator
E2027	Eisai Inc.	Phase 1	Small Molecule	Novel	Synaptic Activity & Neurotransmitters		https://clinicaltrials.gov/ct2/show/NCT02873156	Phosphodiesterase 9A (PDE9) inhibitor
E2609	Eisai Inc. Biogen	Phase 2 Phase 3	Small Molecule	Novel	Misfolded Proteins	Amyloid	https://ClinicalTrials.gov/show/NCT02322021 NCT03036280 https://clinicaltrials.gov/show/NCT02956486	Elenbecestat BACE1 inhibitor
Etanercept *	University of Southampton	Phase 2	Small Molecule	Repurposed	Inflammation	Systemic Inflammation	https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-002145-63/GB	Enbrel™ TNF-alpha inhibitor
Exendin-4	National Institute on Aging (NIA) National Institutes of Health Clinical Center (CC)	Phase 2 completed	Small Molecule	Repurposed	Mitochondria & Metabolic Function		https://ClinicalTrials.gov/show/NCT01255163 https://clinicaltrials.gov/ct2/show/NCT02847403	Exenatide, Byetta, Bydureon GLP-1 receptor agonist

Formoterol	Palo Alto Veterans Institute for Research Alzheimer's Association Mylan Inc.	Phase 2	Small Molecule	Repurposed	Synaptic Activity & Neurotransmitters		https://ClinicalTrials.gov/show/NCT02500784	β-2 adrenergic receptor agonist
Gantenerumab	Hoffmann-La Roche	Phase 3	Biologic	Novel	Misfolded Proteins	Amyloid	https://ClinicalTrials.gov/show/NCT01224106 https://clinicaltrials.gov/show/NCT02051608	RO4909832, RG1450
Gantenerumab Solanezumab	Washington University School of Medicine Eli Lilly and Company Hoffmann-La Roche Alzheimer's Association National Institute on Aging (NIA) Avid Radiopharmaceuticals Accelerating Medicines Partnership (AMP)	Phase 2 Phase 3	Biologic	Novel (Combination Therapy)	Misfolded Proteins	Amyloid	https://ClinicalTrials.gov/show/NCT01760005	
GC021109 *	GliaCure, Inc.	Phase 1 completed	Small Molecule	Novel	Inflammation	Neuroinflammation	https://ClinicalTrials.gov/show/NCT02386306	P2Y6 agonist
Gemfibrozil	Gregory Jicha University of Kentucky	Phase 1	Small Molecule	Repurposed	Vascular		https://ClinicalTrials.gov/show/NCT02045056	Micro-RNA pathways modulator
Grape Seed Polyphenolic Extract Resveratrol	Johns Hopkins University Icahn School of Medicine at Mount Sinai	Phase 1	Natural Product	Other (Combination Therapy)	Mitochondria & Metabolic Function		https://clinicaltrials.gov/ct2/show/NCT02502253	
Guanfacine	Imperial College London	Phase 3	Small Molecule	Repurposed	Synaptic Activity & Neurotransmitters		https://ClinicalTrials.gov/show/NCT03116126	Noradrenergic add-on therapy
GV1001	GemVax & Kael	Phase 2	Biologic	Repurposed	Neuroprotection	Oxidative Stress	https://ClinicalTrials.gov/show/NCT03184467	Telomerase vaccine, cellular proliferation inducer, anti-apoptotic effects, mitochondrial stabilizer, anti-aging and antioxidant effects
HTL0009936	Heptares Therapeutics Limited P1vital Limited	Phase 1	Small Molecule	Novel	Synaptic Activity & Neurotransmitters		https://ClinicalTrials.gov/show/NCT02546310	Muscarinic M1 receptor agonist

Icosapent ethyl (IPE)	VA Office of Research and Development University of Wisconsin, Madison	Phase 2 Phase 3	Small Molecule	Other	Vascular		https://ClinicalTrials.gov/show/NCT02719327	Eicosapentaenoic acid, CLNA-001-15S, CX001261 Derivative of omega-3 fatty acid
Insulin (Humulin R U-100) *	University of Southern California National Institute on Aging (NIA) Alzheimer's Therapeutic Research Institute (ATRI) Wake Forest School of Medicine	Phase 2 Phase 3	Biologic	Repurposed	Mitochondria & Metabolic Function		https://ClinicalTrials.gov/show/NCT01767909	
Insulin aspart	Wake Forest School of Medicine National Institute on Aging (NIA) General Electric	Phase 1	Biologic	Repurposed	Mitochondria & Metabolic Function		https://ClinicalTrials.gov/show/NCT02462161	Detemir, Levemir, Humulin, Novolin
Insulin detemir	Wake Forest School of Medicine Alzheimer's Association	Phase 2	Biologic	Repurposed	Mitochondria & Metabolic Function		https://ClinicalTrials.gov/show/NCT01595646	Increases insulin signaling in the brain
Insulin glulisine	HealthPartners Institute for Education and Research	Phase 2	Biologic	Repurposed	Mitochondria & Metabolic Function		https://ClinicalTrials.gov/show/NCT02503501	Increases insulin signaling in the brain
IONIS MAPTRx	Ionis Pharmaceuticals, Inc.	Phase 1 Phase 2	Biologic	Novel	Misfolded Proteins	Tau	https://ClinicalTrials.gov/show/NCT03186989	ISIS 814907-CS1 Antisense oligonucleotide
JNJ-54861911	Janssen Research & Development, LLC Shionogi Pharma	Phase 2 Phase 3	Small Molecule	Novel	Misfolded Proteins	Amyloid	https://ClinicalTrials.gov/show/NCT02569398 https://clinicaltrials.gov/show/NCT02406027	BACE Inhibitor
KHK6640	Kyowa Hakko Kirin Company, Limited	Phase 1	Biologic	Novel	Misfolded Proteins	Amyloid	https://clinicaltrials.gov/show/NCT02127476 https://ClinicalTrials.gov/show/NCT02377713	
L-Serine	Dartmouth-Hitchcock Medical Center Brain Chemistry Laboratories, Institute for Ethnomedicine	Phase 2	Natural Product	Other	Neuroprotection		https://ClinicalTrials.gov/show/NCT03062449	Non-essential amino acid

Lanabecestat	Eli Lilly and Company AstraZeneca	Phase 3	Small Molecule	Novel	Misfolded Proteins	Amyloid	https://ClinicalTrials.gov/show/NCT02245737 https://clinicaltrials.gov/show/NCT02783573 https://clinicaltrials.gov/show/NCT02972658	LY3314814, AZD3293 BACE inhibitor
Levetiracetam	University of California, San Francisco	Phase 2	Small Molecule	Repurposed	Synaptic Activity & Neurotransmitters		https://ClinicalTrials.gov/show/NCT02002819	Pre-synaptic calcium channel inhibitor
Liraglutide *	Imperial College London King's College Hospital NHS Trust University of Oxford University of Southampton Avon and Wiltshire Mental Health Partnership NHS Trust	Phase 2	Small Molecule	Repurposed	Mitochondria & Metabolic Function		https://ClinicalTrials.gov/show/NCT01843075	GLP-1 receptor agonist
LM11A-31 *	Pharmatropix	Phase 1 Phase 2	Small Molecule	Novel	Neuroprotection	Growth/Neurotrophic Factors	https://ClinicalTrials.gov/show/NCT03069014 https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-005263-16/AT	
Lu AE58054	H. Lundbeck A/S Otsuka Pharmaceutical	Phase 3 completed	Small Molecule	Novel	Synaptic Activity & Neurotransmitters		https://clinicaltrials.gov/show/NCT02006654	Idalopirdine 5-HT6 receptor antagonist
Lu AE58054 Memantine	H. Lundbeck A/S Otsuka Pharmaceutical	Phase 3	Small Molecule	Novel (Combination Therapy)	Synaptic Activity & Neurotransmitters		https://ClinicalTrials.gov/show/NCT02079246	Idalopirdine 5-HT6 receptor antagonist
Lu AF20513	H. Lundbeck A/S	Phase 1	Biologic	Novel	Misfolded Proteins	Amyloid	https://ClinicalTrials.gov/show/NCT02388152	
LY3002813	Eli Lilly and Company	Phase 1	Biologic	Novel	Misfolded Proteins	Amyloid	https://ClinicalTrials.gov/show/NCT02624778 https://ClinicalTrials.gov/show/NCT01837641	N3pG-A β monoclonal antibody
LY3202626	Eli Lilly and Company	Phase 2	Small Molecule	Novel	Misfolded Proteins	Amyloid	https://ClinicalTrials.gov/show/NCT02791191	BACE inhibitor
LY3303560	Eli Lilly and Company	Phase 1	Biologic	Novel	Misfolded Proteins	Tau	https://ClinicalTrials.gov/show/NCT02754830	Tau antibody
Masitinib	AB Science	Phase 3 completed	Small Molecule	Repurposed	Inflammation	Neuroinflammation	https://ClinicalTrials.gov/show/NCT01872598	Tyrosine kinase inhibitor
MEDI1814	AstraZeneca Eli Lilly and Company	Phase 1 completed	Biologic	Novel	Misfolded Proteins	Amyloid	https://ClinicalTrials.gov/show/NCT02036645	Monomeric amyloid binder

Meganatural-Az Grapeseed Extract	Hillel Grossman, Icahn School of Medicine at Mount Sinai National Center for Complementary and Integrative Health (NCCIH)	Phase 2	Natural Product	Other	Misfolded Proteins	Amyloid	https://clinicaltrials.gov/ct2/show/NCT02033941	Anti-oligomerization agent
Mesenchymal Stem Cells (Allogeneic)	Longeveron LLC Stemedica Cell Technologies, Inc. Stemedica International SA	Phase 1 Phase 2	Cell Therapy	Novel	Neuroprotection		https://ClinicalTrials.gov/show/NCT02600130 https://clinicaltrials.gov/show/NCT02833792	Allogeneic Human Mesenchymal Stem Cell Infusion
Mesenchymal Stem Cells (Umbilical Cord)	South China Research Center for Stem Cell and Regenerative Medicine Third Affiliated Hospital, Sun Yat-Sen University Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University Guangzhou Psychiatric Hospital Medipost Co Ltd.	Phase 1 Phase 2	Cell Therapy	Novel	Neuroprotection		https://ClinicalTrials.gov/show/NCT02672306 https://clinicaltrials.gov/show/NCT02513706 https://clinicaltrials.gov/show/NCT02054208 https://ClinicalTrials.gov/show/NCT03172117	Human Umbilical Cord-Derived Mesenchymal Stem Cells
Methylene Blue	Peter Fox Texas Alzheimer's Research and Care Consortium (TARCC) The University of Texas Health Science Center at San Antonio	Phase 2	Small Molecule	Repurposed	Misfolded Proteins	Proteostasis	https://ClinicalTrials.gov/show/NCT02380573	
Minocycline	King's College London	Phase 2	Small Molecule	Repurposed	Inflammation	Neuroinflammation	https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-000397-30/GB	Acnamino
MLC901	National University Hospital, Singapore	Phase 2	Natural Product	Other	Neuroprotection	Neuronal Regeneration & Repair	https://ClinicalTrials.gov/show/NCT03038035	Neuroaid II
MSDC-0160 *	Metabolic Solutions Development Company	Phase 2 completed	Small Molecule	Novel	Mitochondria & Metabolic Function		https://clinicaltrials.gov/ct2/show/NCT01374438	Mitoglitazone mTOT modulator

NewGam 10% IVIG	Sutter Health	Phase 2	Biologic	Other	Misfolded Proteins	Amyloid	https://ClinicalTrials.gov/show/NCT01300728	
NGP 555	NeuroGenetic Pharmaceuticals Inc WCCT Global	Phase 1 completed	Small Molecule	Novel	Misfolded Proteins	Amyloid	https://ClinicalTrials.gov/show/NCT02537938	Gamma-secretase modulator
Nicotinamide	University of California, Irvine	Phase 2	Natural Product	Other	Mitochondria & Metabolic Function		https://ClinicalTrials.gov/show/NCT03061474	Vitamin B3
Nicotine Transdermal Patch *	University of Southern California National Institute on Aging (NIA) Vanderbilt University Alzheimer's Therapeutic Research Institute	Phase 2	Natural Product	Other	Synaptic Activity & Neurotransmitters		https://ClinicalTrials.gov/show/NCT02720445	Nicotinic acetylcholine receptor agonist
Nilotinib *	Georgetown University	Phase 2	Small Molecule	Repurposed	Misfolded Proteins	Proteostasis	https://clinicaltrials.gov/show/NCT02947893	Tasinga® Tyrosine kinase inhibitor, c-abl inhibitor
Nilvadipine *	University of Dublin, Trinity College Molecular Medicine Ireland LBG Alzheimer Europe Archer Pharmaceuticals, Inc. E-Search Limited University College Dublin GABO:mi King's College London Istituto Di Ricerche Farmacologiche Mario Negri University Hospital, Lille University of Ulm Szeged University Goeteborgs Universitet University College Cork Aristotle University Of Thessaloniki Stichting Katholieke Universiteit	Phase 3 completed	Small Molecule	Repurposed	Vascular		https://clinicaltrials.gov/ct2/show/NCT02017340	Nilvad, Nivadil, ARC029 Calcium channel blocker

NP001	Neuraltus Pharmaceuticals, Inc.	Phase 1	Small Molecule	Novel	Inflammation	Systemic Inflammation	https://clinicaltrials.gov/ct2/show/NCT03179501	Stabilized, pH adjusted sodium chlorite Immune regulator of inflammatory monocytes/macrophages
NPT088	Proclara Biosciences, Inc. Alzheimer's Association	Phase 1	Biologic	Novel	Misfolded Proteins	Amyloid, Tau	https://ClinicalTrials.gov/show/NCT03008161	Fusion protein combining GAIM with the backbone of a human immunoglobulin
Omega-3 PUFA	Oregon Health and Science University National Institute on Aging (NIA)	Phase 2	Natural Product	Other	Vascular		https://clinicaltrials.gov/ct2/show/NCT01953705	Omega-3 polyunsaturated fatty acids, fish oil
ORY-2001 *	Oryzon Genomics	Phase 1	Small Molecule	Novel	Genetics & Epigenetics	Epigenetics	https://www.oryzon.com/en/news/oryzon-presents-final-data-phase-i-trial-ory-2001-alzheimer%E2%80%99s-association-international	LSD1/MOA-B inhibitor
Oxaloacetate (OAA)	Russell Swerdlow, MD University of Kansas Medical Center	Phase 1	Natural Product	Other	Mitochondria & Metabolic Function		https://ClinicalTrials.gov/show/NCT02593318	
PF-05251749	Pfizer	Phase 1 completed	Small Molecule	Novel	Unknown		https://clinicaltrials.gov/ct2/show/NCT02691702	Casein kinase I delta/epsilon
PF-06648671	Pfizer	Phase 1 completed	Small Molecule	Novel	Misfolded Proteins	Amyloid	https://clinicaltrials.gov/ct2/show/NCT02407353	Gamma-secretase modulator
PF-06751979	Pfizer	Phase 1 completed	Small Molecule	Novel	Unknown		https://clinicaltrials.gov/show/NCT02793232	Speculation this is an enzyme inhibitor
Pioglitazone	Takeda Pharmaceutical Company Zinfandel Pharmaceuticals Inc.	Phase 3	Small Molecule	Repurposed	Mitochondria & Metabolic Function		https://ClinicalTrials.gov/show/NCT01931566 https://ClinicalTrials.gov/show/NCT02284906	AD4833, Actos®, Glustin™, Piozone®
Piromelatine	Neurim Pharmaceuticals Ltd.	Phase 2	Small Molecule	Repositioned	Synaptic Activity & Neurotransmitters		https://ClinicalTrials.gov/show/NCT02615002	Neu-P11 Melatonin MT ₁ /MT ₂ and serotonin 5-HT _{1A} /5-HT _{1D} receptor agonist
Plasma	Stanford University Alkahest, Inc.	Phase 1	Biologic	Other	Inflammation	Systemic Inflammation	https://clinicaltrials.gov/ct2/show/NCT02256306	
Posiphen	QR Pharma Inc. Alzheimer's Disease Cooperative Study (ADCS)	Phase 1 Phase 2	Small Molecule	Novel	Misfolded Proteins	Amyloid, Tau, Synuclein	https://ClinicalTrials.gov/show/NCT02925650	QR15001, ADC-042-DISC Selective inhibitor of APP production

PQ912	Probiodrug AG Julius Clinical VU University Medical Center Amsterdam	Phase 2 completed	Small Molecule	Novel		Misfolded Proteins	Amyloid	https://ClinicalTrials.gov/show/NCT02389413	Glutamyl-peptide cyclotransferase inhibitor, targeting pyroglutamate amyloid (pGlu-Abeta)
Probucol	Douglas Mental Health University Institute Weston Brain Institute McGill University	Phase 1 Phase 2	Small Molecule	Repurposed		Genetics & Epigenetics	ApoE	https://clinicaltrials.gov/ct2/show/NCT02707458	Anti-hyperlipidemic, promotes ApoE availability in CSF
PXT00864	Pharnext SA Ascopharm Groupe Novasco	Phase 2 completed	Small Molecule	Repurposed (Combination Therapy)		Synaptic Activity & Neurotransmitters		https://clinicaltrials.gov/ct2/show/NCT02361242	Combination of acamprosate Ca2+ (analog of GABA) and baclofin (GABA-B activator)
Rasagiline *	The Cleveland Clinic	Phase 2	Small Molecule	Repurposed		Neuroprotection		https://ClinicalTrials.gov/show/NCT02359552	(MAO-B) Monoamine oxidase B inhibitor
Riluzole *	Rockefeller University	Phase 2	Small Molecule	Repurposed		Synaptic Activity & Neurotransmitters		https://ClinicalTrials.gov/show/NCT01703117	Protects against glutamate excitotoxicity, recovers EAAT2 gene expression
RO 7105705	Genentech, Inc.	Phase 1 completed	Biologic	Novel		Misfolded Proteins	Tau	https://ClinicalTrials.gov/show/NCT02820896	RG 6100
Rotigotine *	Santa Lucia Foundation	Phase 2	Small Molecule	Repurposed		Synaptic Activity & Neurotransmitters			Dopaminergic therapy
RVT-101	Axovant Sciences Ltd.	Phase 2 Phase 3	Small Molecule	Novel		Synaptic Activity & Neurotransmitters		https://ClinicalTrials.gov/show/NCT02586909 https://clinicaltrials.gov/show/NCT02910102 https://clinicaltrials.gov/show/NCT02585934	Intepirdine 5-HT6 receptor antagonist
S -Equol	Russell Swerdlow, MD Ausio Pharmaceuticals, LLC University of Kansas Medical Center	Phase 1 Phase 2	Natural Product	Other		Neuroprotection		https://clinicaltrials.gov/show/NCT03101085	Estrogen receptor β (ER β) agonist
SAR228810	Sanofi	Phase 1 completed	Biologic	Novel		Misfolded Proteins	Amyloid	https://clinicaltrials.gov/ct2/show/NCT01485302	Monoclonal antibody, amyloid fibrillogenesis inhibitor
Sargramostim *	University of Colorado, Denver The Dana Foundation	Phase 2	Biologic	Repurposed		Inflammation	Systemic Inflammation	https://ClinicalTrials.gov/show/NCT01409915	GM-CSF, Leukine Granulocyte colony stimulator, promotes amyloid clearance

Simvastatin	University of Wisconsin, Madison National Institute on Aging (NIA)	Phase 2	Small Molecule	Repurposed	Vascular	https://clinicaltrials.gov/ct2/show/NCT00939822	HMG-CoA reductase inhibitor (statin)	
Simvastatin + L-Arginine + Tetrahydrobiopterin	University of Massachusetts, Worcester	Phase 2	Small Molecule + Natural Product	Repurposed + Other (Combination Therapy)	Vascular	https://ClinicalTrials.gov/show/NCT01439555	Combination of HMG-CoA reductase inhibitor and antioxidant	
Sodium oligo-mannurate	Shanghai Greenvally Pharmaceutical Co., Ltd.	Phase 3	Small Molecule	Novel	Misfolded Proteins	Amyloid	https://ClinicalTrials.gov/show/NCT02293915	GV-971 Amyloid aggregation inhibitor, reduces AChE activity
STA-1 Donepezil	Sinphar Pharmaceutical Co., Ltd	Phase 2	Small Molecule	Repurposed + Donepezil (Combination Therapy)	Neuroprotection	Oxidative Stress	https://clinicaltrials.gov/show/NCT01255046	Antioxidant properties of echinascoside, anti-inflammatory
SUVN-502	Suven Life Sciences Limited	Phase 2	Small Molecule	Novel	Synaptic Activity & Neurotransmitters		https://ClinicalTrials.gov/show/NCT02580305	CTP2S1502HT6 Selective 5-HT6 receptor antagonist
T-817 MA	Toyama Chemical Co., Ltd. Alzheimer's Disease Cooperative Study (ADCS)	Phase 2 completed	Small Molecule	Novel	Neuroprotection		https://ClinicalTrials.gov/show/NCT02079909	Neurotrophic agent, sigma receptor agonist
T3D-959	T3D Therapeutics, Inc.	Phase 1 Phase 2	Small Molecule	Novel	Mitochondria & Metabolic Function		https://ClinicalTrials.gov/show/NCT02560753	PPARdelta/gamma agonist (PPAR activation boosts insulin sensitivity and regulates triglyceride levels)
Tadalafil *	St. George's, University of London Alzheimer's Drug Discovery Foundation Alzheimer's Society UK University of Copenhagen University of Glasgow St George's University Hospitals NHS Foundation Trust	Phase 2	Small Molecule	Repurposed	Vascular		https://clinicaltrials.gov/ct2/show/NCT02450253	CIALIS® PDE5 inhibitor
TAK-071 Donepezil	Takeda	Phase 1	Small Molecule	Novel + Donepezil (Combination Therapy)	Synaptic Activity & Neurotransmitters		https://ClinicalTrials.gov/show/NCT02769065	Muscarinic M1 receptor positive allosteric modulator

Telmisartan	Emory University	Phase 1	Small Molecule	Repurposed	Vascular		https://ClinicalTrials.gov/show/NCT02471833	Angiotensin 2 receptor antagonist
Telmisartan Perindopril *	Dr. Sandra E Black Alzheimer's Drug Discovery Foundation Sunnybrook Health Sciences Centre	Phase 2	Small Molecule	Repurposed	Vascular		https://ClinicalTrials.gov/show/NCT02085265	Comparative effectiveness study of angiotensin 2 receptor antagonist (Telmisartan) and ACE inhibitor (Perindopril)
TPI-287	University of California, San Francisco	Phase 1	Small Molecule	Novel	Misfolded Proteins	Tau	https://ClinicalTrials.gov/show/NCT01966666	Next generation taxane Microtubule stabilizer, tubulin-binding
TRx0237	TauRx Therapeutics Ltd	Phase 3	Small Molecule	Repurposed	Misfolded Proteins	Tau	https://ClinicalTrials.gov/show/NCT02245568	LMTM and LMT-X, purified form of methylene blue Tau aggregation inhibitor (or potentially dissolver)
UB-311	United Neuroscience Ltd.	Phase 2	Biologic	Novel	Misfolded Proteins	Amyloid	https://clinicaltrials.gov/show/NCT02551809	Synthetic peptide vaccine
Valaciclovir	Hugo Lovheim Umeå University	Phase 2	Small Molecule	Repurposed	Inflammation	Systemic Inflammation	https://ClinicalTrials.gov/show/NCT02997982	Prodrug of acyclovir Anti-viral, herpes virus nucleoside analog DNA polymerase inhibitor
Verubecestat	Merck Sharp & Dohme Corp.	Phase 3	Small Molecule	Novel	Misfolded Proteins	Amyloid	https://clinicaltrials.gov/show/NCT01953601	MK-8931 BACE1 inhibitor
Vorinostat	German Center for Neurodegenerative Diseases (DZNE) University Hospital, Bonn University of Göttingen	Phase 1	Small Molecule	Repurposed	Genetics & Epigenetics	Epigenetics	https://ClinicalTrials.gov/show/NCT03056495	N-hydroxy-N'-phenyl-octanediamide HDAC inhibitor, antineoplastic
VU319 *	Vanderbilt University Vanderbilt University Medical Center	Phase 1	Small Molecule	Novel	Synaptic Activity & Neurotransmitters		https://clinicaltrials.gov/ct2/show/NCT03220295	VU0467319 M1 Positive Allosteric Modulator
VX-745	EIP Pharma, LLC	Phase 2 completed	Small Molecule	Repurposed	Inflammation	Neuroinflammation	https://clinicaltrials.gov/show/NCT02423200	Neflamapomid P38 mitogen-activated protein kinase inhibitor (inhibits the alpha isoform of p38 MAPK)
Xanamem	Actinogen Medical ICON Clinical Research	Phase 2	Small Molecule	Novel	Neuroprotection		https://clinicaltrials.gov/show/NCT02727699	11-HSD1 enzyme activity inhibitor